Bexarotene is a retinoid medication indicated for the treatment of cutaneous manifestations of T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. It works by binding to retinoid X receptors (RXRs), influencing cell differentiation and apoptosis in malignant T-cells.
Bexarotene is administered orally, and dosage must be tailored by the treating physician based on individual patient response and tolerance.